• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia
Date: June 18, 2018 Issue #:  1549Summary:  The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag– Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium(Livalo), which was approved in 2009.1Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in ...
Source: The Medical Letter - June 11, 2018 Category: Drugs & Pharmacology Authors: admin Source Type: research

The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients
Curr Issues Mol Biol. 2023 Apr 5;45(4):3146-3167. doi: 10.3390/cimb45040205.ABSTRACTMany investigations have discovered a connection between statins and magnesium supplements. On one hand, increasing research suggests that chronic hypomagnesemia may be an important factor in the etiology of some metabolic illnesses, including obesity and overweight, insulin resistance and type 2 diabetes mellitus, hypertension, alterations in lipid metabolism, and low-grade inflammation. Chronic metabolic problems seem to be prevented by a high Mg intake combined with diet and/or supplements. On the other hand, it is known that statins low...
Source: Mol Biol Cell - May 15, 2023 Category: Molecular Biology Authors: Roxana Nartea Brindusa Ilinca Mitoiu Ioana Ghiorghiu Source Type: research